{"filing":{"accession_number":"0001104659-26-078511","cik":"0001737953","ticker":"REPL","company_name":"Replimune Group, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"tm2619129d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926078511/tm2619129d1_8k.htm"},"events":[{"id":14485,"run_id":12897,"accession_number":"0001104659-26-078511","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Replimune's financial results for the fiscal fourth quarter and year ended March 31, 2026. The Item 2.02 filing includes a news release (Exhibit 99.1) announcing consolidated statements of operations, balance sheet data, and detailed financial metrics including R\u0026D expenses ($221.2M), SG\u0026A expenses ($98.7M), and net loss ($313.9M). The disclosure is material as it provides investors with comprehensive financial performance data for the fiscal year.","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11943,"accession_number":"0001104659-26-078511","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Replimune's financial results for the fiscal fourth quarter and year ended March 31, 2026. The Item 2.02 filing includes a news release (Exhibit 99.1) announcing consolidated statements of operations, balance sheet data, and detailed financial metrics including R\u0026D expenses ($221.2M), SG\u0026A expenses ($98.7M), and net loss ($313.9M). The disclosure is material as it provides investors with comprehensive financial performance data for the fiscal year.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:12:37.418809+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11943,"accession_number":"0001104659-26-078511","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Replimune's financial results for the fiscal fourth quarter and year ended March 31, 2026. The Item 2.02 filing includes a news release (Exhibit 99.1) announcing consolidated statements of operations, balance sheet data, and detailed financial metrics including R\u0026D expenses ($221.2M), SG\u0026A expenses ($98.7M), and net loss ($313.9M). The disclosure is material as it provides investors with comprehensive financial performance data for the fiscal year.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:12:37.418809+00:00","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-06-29"}]}